Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
October 16, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio,...
Microchip Releases 20 Advanced Wi-Fi® Products for Industrial and Commercial Applications
October 15, 2024 08:02 ET
|
Microchip Technology Inc.
Microchip’s comprehensive support ecosystem and robust portfolio of Wi-Fi products and services is unmatched in the industry today.
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
October 15, 2024 08:00 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory...
Global Cancer Gene Therapy Market Set for Significant Growth, Projected to Reach USD 3,142.2 Million by 2034 Driven by Personalized Medicine and Targeted Therapies | Future Market Insights, Inc.
October 14, 2024 09:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The global cancer gene therapy market is poised for robust expansion, with sales projected to rise from USD 1,822.2 million in 2024 to an impressive...
Bispecific Antibody Drug Conjugates Market Opportunity Outlook 2024-2029: China Leads Over 35 Candidates, Key Companies Pioneering BsADC are Amgen, Innovent Biologics, AstraZeneca
October 14, 2024 05:52 ET
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to...
Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
October 11, 2024 16:00 ET
|
Nurix Therapeutics, Inc.
Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom’s...
EpimAb Biotherapeutics Announces Upcoming Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 10, 2024 21:00 ET
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI, Oct. 11, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to...
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
October 10, 2024 16:05 ET
|
Sutro Biopharma, Inc.
Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations STRO-004 (tissue factor ADC) preclinical data has demonstrated greater...
Antibody Drug Conjugates Industry Report (2024-2032) Featuring Profiles the Top 13 Players - ADC Therapeutics, Astellas Pharma, AstraZeneca, Celldex Therapeutics, Roche & More
October 09, 2024 10:13 ET
|
Research and Markets
Dublin, Oct. 09, 2024 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Report by Component, Target, Application, End-user, and Region 2024-2032" report has been added to ...
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
October 07, 2024 16:05 ET
|
Vincerx Pharma, Inc.
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program’s potential and validating the VersAptx™...